5,730 Shares in Pulmonx Co. (NASDAQ:LUNG) Acquired by 272 Capital LP

272 Capital LP purchased a new stake in Pulmonx Co. (NASDAQ:LUNG) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,730 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in LUNG. nVerses Capital LLC bought a new position in Pulmonx during the 3rd quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Pulmonx in the 2nd quarter valued at approximately $37,000. Hsbc Holdings PLC acquired a new position in Pulmonx during the 2nd quarter worth approximately $93,000. Mackenzie Financial Corp bought a new position in shares of Pulmonx during the 2nd quarter worth approximately $102,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Pulmonx in the third quarter valued at approximately $102,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Stock Down 1.5 %

Pulmonx stock opened at $5.96 on Friday. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company’s 50-day moving average is $6.59 and its 200-day moving average is $6.90.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period last year, the firm posted ($0.39) earnings per share. On average, analysts anticipate that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total transaction of $130,400.00. Following the sale, the director now directly owns 1,091,974 shares of the company’s stock, valued at approximately $7,119,670.48. This represents a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,376 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.18, for a total value of $27,043.68. Following the completion of the transaction, the insider now directly owns 291,057 shares of the company’s stock, valued at approximately $1,798,732.26. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 49,873 shares of company stock worth $324,070 over the last three months. Insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on LUNG. Wells Fargo & Company reduced their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday. Citigroup restated a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a report on Wednesday. Finally, Stifel Nicolaus dropped their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Pulmonx has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.